Recent Updates
Recently added Catalysts
ERAS Negative Sentiment Score: 25/100

ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Erasca, Inc. on behalf of its stockholders due to claims of possible federal securities violations. This comes after Erasca disclosed a patent infringement letter from Revolution Medicines regarding its Phase 1 drug, ERAS-0015, leading to a significant stock price drop of 48%. Investors who have incurred losses are encouraged to contact the law firm for more information on their rights and options.

Market Sentiment Analysis

CONCERNS & RISKS

  • Erasca's stock price fell by approximately 48% following the patent infringement claims.
  • The investigation indicates potential violations of federal securities laws by Erasca.
  • The company is facing serious allegations related to trade secret misappropriation.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Erasca (ERAS) To Contact Him Directly To Discuss Their Options
If you purchased or acquired stock in Erasca and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) on behalf of Erasca stockholders. Our investigation concerns whether Erasca has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On April 28, 2026, Erasca disclosed that it had received a letter from Revolution Medicines alleging that Erasca’s ERAS-0015—a Phase 1 oral pan-RAS molecular glue inhibitor designed to target cancers—infringes a Revolution patent and is associated with alleged trade secret misappropriation. Following this disclosure, Erasca’s share price declined by $9.25 per share, or approximately 48%, falling from $19.15 per share on April 27, 2026 to close at $9.90 per share on April 28, 2026.
If you purchased or otherwise acquired Erasca shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who should investors contact about Erasca losses?

Investors should contact Brandon Walker or Melissa Fortunato at Bragar Eagel & Squire.

What allegations is Erasca facing?

Erasca is accused of infringing a patent and misappropriating trade secrets.

How much did Erasca's stock price drop?

Erasca's stock price fell by $9.25, a decline of about 48%.

What is the focus of Bragar Eagel & Squire's investigation?

The investigation seeks to determine if Erasca violated federal securities laws.

Is there a cost to discuss Erasca claims?

No, there is no cost or obligation to discuss potential claims with the firm.

Last updated: May 14, 2026